摘要
新冠疫情暴发以来,我国新冠疫苗的研发进程在国际上始终处于第一梯队,为世界抗疫提供了有力的支持。当前国产新冠疫苗在临床试验和真实世界的研究中均表现出较好的保护效力和安全性,但由于疫苗保护效力持续时间的不确定性以及多种变异毒株的出现,国产疫苗仍面临诸多挑战。利用同源疫苗加强免疫可提高疫苗的保护效果,但长期来看应加快研发包含多种变异毒株的多价疫苗以及新冠病毒通用疫苗,同时尽快开展科学规范的新冠疫苗安全性的主动监测,科学评估新冠疫苗的长期安全性。
Since the outbreak of COVID-19,China has been leading the world in vaccines research,providing a powerful tool for epidemic prevention.The domestic COVID-19 vaccine displays acceptable and efficient protection and safety in clinical trials and real world research.However,there are still many challenges for domestic vaccines due to uncertainty about the duration of protection and effectiveness against multiple variant strains.Using a homologous vaccine to enhance immunity is feasible to deal with the immediate situation,however,in the long run,it is necessary to speed up the development of multivalent and universal vaccines for COVID-19.At the same time scientific and standardized safety monitoring is necessary as a priority so as to accurately assess the longterm safety of domestic vaccines.
作者
石梓薇
黄娇
魏晟
Zi-Wei SHI;Jiao HUANG;Sheng WEI(School of Public Health,Tongji Medical College,Huazhong University of Science and Technology,Wuhan 430030,China;Center for Evidence-Based and Translational Medicine,Zhongnan Hospital of Wuhan University,Wuhan 430071,China)
出处
《医学新知》
CAS
2022年第1期53-57,共5页
New Medicine
基金
国家自然科学基金项目(82003518)。